International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Pages 38-42 , April 2010

Metabolic syndrome in type 1 diabetes

  • Sujoy Ghosh

      Affiliations

    • Diabetes Day Centre, The Ayr Hospital, Dalmellington Road, Ayr, Scotland KA6 6DX, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 1292 610555; fax: +44 1292 614538.
    • ,
  • Andrew Collier

      Affiliations

    • Diabetes Day Centre, The Ayr Hospital, Dalmellington Road, Ayr, Scotland KA6 6DX, United Kingdom
    • ,
  • Mario Hair

      Affiliations

    • Department of Physical Sciences, University of the West of Scotland, United Kingdom
    • ,
  • Iqbal Malik

      Affiliations

    • Diabetes Day Centre, The Ayr Hospital, Dalmellington Road, Ayr, Scotland KA6 6DX, United Kingdom
    • ,
  • Tarik Elhadd

      Affiliations

    • Diabetes Day Centre, The Ayr Hospital, Dalmellington Road, Ayr, Scotland KA6 6DX, United Kingdom

Received 28 July 2009 ,Revised 14 October 2009 ,Accepted 24 October 2009.

References 

  1. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome; 2003. <http://www.idf.org/webdata/docs/IDF_Meta_def_final.pdf> [accessed 10.10.08].
  2. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486–97.
  3. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet. 2005;366:1778
  4. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva (Switzerland): Department of Noncommunicable Disease Surveillance; 1999.
  5. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation. 2005;25(112):2735–2752
  6. Isomaa B, Almgren P, Tuomi T, Forse´n B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab Care. 2001;24:683–689
  7. Lakka H-M, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709–2716
  8. Bruno G, Merletti F, Biggeri A, Bargero G, Ferrero S, Runzo C, et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diab Care. 2004;27(11):2689–2694
  9. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diab Med. 2003;52–58
  10. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial. Diab Care. 2007;30(3):707–712
  11. Teupe B, Bergis K. Epidemiological evidence for “double diabetes”. Lancet. 1991;337:361–362
  12. Orchard TJ, Chang YF, Ferrell RE, Petro N, Ellis DE. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities?. Kidney Int. 2002;62:963–970
  13. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KYZ, Kinder LS, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diab Care. 2003;26:1374–1379
  14. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Morrjani S, et al. Hyperinsulinaemia as an independent risk factor for ischaemic heart disease. N Engl J Med. 1996;334:952–957
  15. Bondonna RC. The syndrome of insulin resistance and its links to atherosclerosis. John Wiley and Sons; 2003;
  16. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Geneva: World Health Org., Department of Noncommunicable Disease Surveillance; 1999, p. 31–3.
  17. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, et al. Metabolic syndrome in type 1 diabetes. Association with diabetic nephropathy and glycemic control. Diab Care. 2005;28(8):2019–2024
  18. Saraheimo M, Teppo A-M, Forsblom C, Fagerudd J, Groop P-H FinnDiane Study Group. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia. 2003;46:1402–1407
  19. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diab Care. 2007;30(5):1248–1254
  20. Saely CH, Koch L, Schmid F, Marte T, Aczel S, Langer P, et al. Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diab Care. 2006;29(4):901–907
  21. Yip J, Mattock MB, Morocutti A, Sethi M, Trevisan R, Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet. 1993;342(8876):883–887
  22. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia. 1989;32:219–226
  23. The Scottish Health Survey. In: Cardiovascular disease, vol. 1. Scotland: Information and Statistics; 2003. <http://www.scotland.gov.uk/Resource/Doc/76169/0019727.pdf> [accessed 10.10.08].
  24. Sobal J. Globalization and the epidemiology of obesity. Int J Epidemiol. 2001;30:1136–1137
  25. Sobal J. Social and cultural influences on obesity. In:  Bjorntorp P editors. International textbook of obesity. New York: John Wiley and Sons; 2001;p. 305–322
  26. Pambianco G, Costacou T, Orchard TJ. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diab Care. 2007;30(5):1248–1254
  27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–986
  28. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol. 1995;75(14):894–903
  29. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA. 1998;280(2):140–146
  30. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643–2653
  31. Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diab Care. 2006;29(12):2701–2707
  32. Davis TM, Bruce DG, Davis WA. Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: the Fremantle Diabetes Study. Diab Res Clin Pract. 2007;78(3):412–417
  33. McGill M, Molyneaux L, Twigg SM, Yue DK. The metabolic syndrome in type 1 diabetes: does it exist and does it matter?. J Diab Complicat. 2008;22(1):18–23
  34. Reaven GM. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes. 1988;37:1595–1607
  35. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Smithline Kinder L, et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diab Care. 2003;26:1374–1379
  36. UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–865
  37. Cusi K, De Fronzo RA. Metformin: a review of its metabolic effects. Diab Rev. 1998;6:132
  38. Janssen M, Rillaerts E, De Leeuw I. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother. 1991;45(8):363–367
  39. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diab Care. 2003;26(1):138–143
  40. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diab Care. 2005;28(7):1562–1567

PII: S1877-5934(09)00057-5

doi: 10.1016/j.ijdm.2009.10.005

International Journal of Diabetes Mellitus
Volume 2, Issue 1 , Pages 38-42 , April 2010

Article Tools